Uncategorized

LifeMine raises $263M in mission to improve organ transplant aftercare

Published

on

Patients who receive an organ transplant must take difficult immuno-suppressive medicines for the rest of their lives. LifeMine Therapeutics wants to offer a safer alternative.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version